NCT02133352View on ClinicalTrials.gov

Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2014

Conditions
Pulmonary HypertensionDiastolic Left Ventricular Dysfunction
Interventions
DRUG

Ranolazine

Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated

Trial Locations (1)

02118

Boston University Medical Center, Boston

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Boston University

OTHER